New drug for lung scarring passes first safety check in healthy people
NCT ID NCT06310746
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 29 times
Summary
This early-stage study tested a single dose of an experimental drug called HLX6018 in 66 healthy adults to see if it is safe and how the body processes it. The drug is being developed for idiopathic pulmonary fibrosis (IPF), a serious lung-scarring disease. No treatment was given to patients with IPF in this study.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IPF are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
First Hospital of Jilin University
Changchun, Jilin, China
Conditions
Explore the condition pages connected to this study.